Altimmune (ALT) Capital Expenditures (2010 - 2026)

Altimmune (ALT) posted quarterly Capital Expenditures of $21000.0 for Q1 2026, up 2000.0% quarter-over-quarter from $1000.0 in Q4 2025.

Altimmune (ALT) Capital Expenditures (2010 - 2026) Analysis & Trends

Altimmune (ALT) has reported Capital Expenditures for 15 consecutive years, with $21000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Capital Expenditures changed N/A year-over-year to $21000.0; the TTM figure through Mar 2026 stood at $22000.0 (changed N/A YoY), while the FY2025 annual figure was $11000.0, changed N/A from the prior year.
Capital Expenditures climbed to $21000.0 in Q1 2026 per ALT's latest filing, from $1000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $60000.0 in Q3 2022 and bottomed at -$4000.0 in Q2 2023.
Historically, Capital Expenditures has averaged $24375.0 across 4 years, with a median of $20000.0 in 2022.
On a YoY basis, Capital Expenditures climbed as much as 466.67% in 2023 and fell as far as 121.05% in 2023.
Altimmune's Capital Expenditures stood at $38000.0 in 2022, then plunged by 110.53% to -$4000.0 in 2023, then soared by 125.0% to $1000.0 in 2025, then surged by 2000.0% to $21000.0 in 2026.
Business Quant data shows ALT's Capital Expenditures at $21000.0 in Q1 2026, $1000.0 in Q4 2025, and -$4000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	Altimmune	571.75 Mn	571.75 Mn	-	32,000.00

Download Data